A Tool for New Immunotherapy
Not just nutritional support anymore.
R+ Amino acid limited powder featured on Cell Metabolism cover.
(IF:27.7, Cell Metabolism Cover Volume 36 Number 12 December 3, 2024)
For The First Time
It can inhibit tumor growth, enhance antitumor immunity, and have a lasting impact on tumors.
(Marked by )
It can combine with anti-PD-1/PD-L1 immunotherapy to make cancer sensitive to PD-1 treatment.
(Marked by )
Verified through Clinical Trials
Comparison before and after the treatment of an esophageal cancer patient using R+ Amino acid limited powder and immunotherapy.
Proven feasible and safe in clinical trials, with no impacts on the body mass index (BMI) and quality of life of patients.
Overall response rate (ORR) was 25%.
Clinical benefit rate (CBR) was 90%.